For many start-ups, especially those in high-growth tech and life sciences sectors, the corporate governance playbook is often neglected, and viewed as a practice reserved for large, public companies. Thorough and deliberate governance decisions and documents are crucial to any company from the outset, defining the authority, roles and timing of key business decisions.
Join the NACD Philadelphia Chapter to discuss important steps in the creation of a robust governance plan, how to seek out those positive qualities of successful directors, and ways that a strong corporate governance plan can positively affect the company’s bottom line and future growth.
Armando Anido has served as Zynerba Pharmaceutical’s Chairman and Chief Executive Officer(CEO) since October 2014. Mr. Anido has more than 30 years of executive, operational and commercial leadership experience in the biopharmaceutical industry, particularly in leading CNS transdermal patch and gel products through the entire product life cycle. Prior to Zynerba, Mr. Anido served as CEO of two publicly trade companies. Most recently, he was the CEO of NuPathe (NASDAQ: PATH), which was acquired by Teva Pharmaceuticals in February 2014. At NuPathe, he led the company through FDA approval of its lead product, ZecuityÂ®, the first transdermal patch for migraine, to pre-launch before successfully selling the company to Teva. He also served as President and CEO of Auxilium Pharmaceuticals (NASDAQ: AUXL), where under his leadership, sales grew from $42 million in 2005 to more than $260 million in 2011 and market capitalization increased from $200 million to more than $900 million. Prior to Auxilium, Mr. Anido served as Executive Vice President, Sales and Marketing, at MedImmune and prior to that, in senior sales and marketing positions at GlaxoWellcome and Lederle Laboratories. At GlaxoWellcome, he was Vice President, Central Nervous System Marketing, responsible for the commercialization of the epilepsy, migraine and depression businesses in the U.S. He is currently a member of the Board of Directors of PABio, and he was a member of the Board of Directors of Adolor until it was sold to Cubist in December 2011. Mr. Anido earned a BS in Pharmacy and an MBA from West Virginia University.
Rachael M. Bushey is a partner and chair of Life Sciences and vice chair of the Health Sciences Department of Pepper Hamilton LLP, resident in the Philadelphia office.
Ms. Bushey represents public and private life sciences companies in connection with mergers and acquisitions, complex divestitures and carve-out transactions, a variety of capital markets transactions (IPOs, follow-on offerings, PIPEs, RDOs and private placements), Securities Exchange Act work, corporate governance and collaboration agreements. She regularly provides counseling to boards of directors and senior management on a wide range of corporate governance and compliance matters.
In addition, Ms. Bushey has significant experience in negotiating transactions with both pharmaceutical and biotechnology companies in the United States, Europe and Asia.
Ms. Bushey has been a guest speaker on strategic transactions and corporate issues affecting life sciences companies. She also is active in the community.
Prior to Pepper, Ms. Bushey was a partner at Hogan Lovells LLP and also served as vice president, deputy general counsel and corporate secretary for West Pharmaceutical Services, Inc.
Peter B. Davidson has served as the JetPay’s Chief Administrative Officer and Corporate Secretary since its inception and is now the Company’s Vice-Chairman providing strategic leadership, while still retaining his duties as Corporate Secretary. Mr. Davidson has over 30 years of hands-on experience in both the direct management of payment and payroll companies and in management consulting in these businesses.
Mr. Davidson was formerly Chief Executive Officer of Brooks FI Solutions, LLC, an entity that provides retail banking and payment solutions that he founded in 2006. Immediately prior to founding Brooks FI Solutions, Mr. Davidson was Executive Vice President of Genpass, Inc. where, from 2002 until its acquisition and subsequent integration by U.S. Bancorp in 2005, he led its efforts to bring stored value products to market. While at Genpass, Inc., he was also involved in the development and implementation of MoneyPass, a surcharge-free ATM network. Earlier in his career, Mr. Davidson served as President of Speer & Associates, leading domestic and international consulting engagements in the retail banking and electronic funds transfer industry; Executive Vice President at HSBC USA and President of HSBC Mortgage, where he was responsible for managing its consumer businesses; and Senior Vice President at CoreStates Financial, where he managed the credit card and consumer lending businesses and developed remote banking strategies. Mr. Davidson holds a B.S. in Economics from the Wharton School of the University of Pennsylvania in Finance and Accounting, and an MBA from Widener University in Finance.
Wendy F. DiCicco, Chief Operating and Chief Financial Officer
Ms. DiCicco is currently Chief Operating and Chief Financial Officer of Centinel Spine, a global, privately held developer and manufacturer of spinal implants, where she has been since August 2017. From 2014 through 2017, she served as President and Chief Operating Officer of Camber Spine, a privately held spinal implant company. Prior to her roles with Centinel and Camber, from 2008 through 2014, Ms. DiCicco served as Chief Financial Officer of several private, equity backed primarily biotech and medtech companies, including Globus Medical, Nuron Biotech and Quench. From 1996 to 2008, she served as the
principal financial officer of Kensey Nash Corporation (as controller for two years and then as Chief Financial Officer for ten years), a publicly-traded medical technology company specializing in cardiology
and orthopaedics and now part of Royal DSM, a Netherlands company. Ms. DiCicco was an Accounting and Audit Manager with Deloitte LLP from 1990 to 1996, where she served clients in the manufacturing
and retail industries. Ms. DiCicco graduated from Philadelphia College of Textiles and Science with a B.S. degree in Accounting. Ms. DiCicco is a Certified Public Accountant in Pennsylvania and is a member of
AICPA, the PICPA and the NACD. Her board service includes both private (Viking Pure [current] and SynCardia Systems) and public (II-VI, Inc. and Canna Pharma Rx) companies across the medical device
and opto-electronic industries. She has also served on the boards of multiple non-profit organizations, including the Chester Springs Library (current), Chester County Economic Development Council, the
Upper Main Line YMCA and the Philadelphia Chapter of the NACD (current).
Vincent Milano joined Idera as Chief Executive Officer in December 2014. Mr. Milano most recently served as Chairman, President, and Chief Executive Officer of ViroPharma, which was acquired by Shire Pharmaceuticals in January 2014. Under his stewardship, ViroPharma became a leading developer of innovative therapies for rare diseases, with the approval and commercialization of its lead product, Cinryze, for the treatment of hereditary angioedema in the United States and Europe. Mr. Milano joined ViroPharma in 1996 and served as Vice President, Chief Financial Officer, and Treasurer from 1997 to 2006 before becoming Chief Executive Officer. He was instrumental in building the company, including leading efforts to raise nearly $900 million in capital, as well as acquisitions of Lev Pharmaceuticals and the drug Vancocin from Eli Lilly. In addition, he played critical roles in business development and investor relations activities for ViroPharma, and contributed significantly to establishing the strategic focus of the company. Prior to joining ViroPharma, he served as a senior manager at KPMG LLP, an independent registered public accounting firm.
Mr. Milano currently serves on the Boards of Directors of Spark Therapeutics, Vanda Pharmaceuticals, VenatoRx and Life Sciences of PA. He received his Bachelor of Science degree in accounting from Rider College.